Clinical Trials Browser

Phase 2 × Attenuated familial adenomatous polyposis × Erlotinib Hydrochloride × Clear all

NCT02961374 2022-07-26

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Phase 2 Completed

46 enrolled 13 charts

Gastrointestinal

Attenuated familial adenomatous polyposis, Adenomatous Polyposis Coli